Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease
Sponsor: Insmed Incorporated
This PHASE2 trial investigates Mycobacteria, Atypical and Mycobacterium Infections, Nontuberculous and is currently completed. Insmed Incorporated leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Sep 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Insmed Incorporated
- Kevin Winthrop
- The University of Texas Health Science Center at Tyler
For direct contact, visit the study record on ClinicalTrials.gov .